Reactogenicity is comparable for simultaneous and sequential administration of mRNA COVID-19 and influenza vaccines.
The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.
Dr. Robert Jacobson, medical director for Mayo Clinic's Primary Care Immunization Program, clears up some misconceptions about COVID-19 and the flu.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback